To learn more and become a part of the fight against stroke, sign up for our company newsletter for updates and more.
To learn more and become a part of the fight against stroke, sign up for our company newsletter for updates and more.
to learn more and become a part of the fight against stroke, sign up for our company newsletter for updates and more
With hypoxia, seconds make the difference between life and death. We are committed to bridging those moments through the structure of co-polymers. Based on Dr. David Platt's groundbreaking research in carbohydrate chemistry, Bioxytran, Inc is developing treatments for stroke and many other medical situations related to hypoxic conditions.
In the United States, about 795,000 people suffer a stroke each year. Someone has a stroke every 40 seconds, and every 4 minutes someone dies from stroke. There are more than 140,000 deaths each year from stroke.
The key is BioXyTran's two workhorses: BXT-25 and BXT-252. Both drugs are designed to oxygenate ischemic (reduced blood flow) regions of the body and could provide sufferers valuable aid.
Bioxytran Inc., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the lungs, brain, heart, and other vital organs offers a new and possibly life-saving treatment option for late-stage 2019-nCoV.
The Nobel Prize in Physiology or Medicine for 2019 is awarded to William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza. The need for oxygen to sustain life has been understood since the onset of modern biology; but the molecular mechanisms underlying how cells adapt to variations in oxygen supply were unknown until the prize-winning work described here. Animal cells undergo fundamental shifts in gene expression when there are changes in the oxygen levels around them.
Bioxytran Inc. (BIXT) has a novel drug for stroke patients that can restore the supply of oxygen to the brain. Strokes effects over 900,000 people per year and the indirect costs of stroke due to disability and special services are over $22 billion annually.
